Foundry Partners LLC Makes New Investment in Organon & Co. (NYSE:OGN)

Foundry Partners LLC purchased a new position in Organon & Co. (NYSE:OGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 399,494 shares of the company’s stock, valued at approximately $7,642,000.

Several other large investors also recently bought and sold shares of OGN. Friedenthal Financial purchased a new stake in Organon & Co. in the 2nd quarter valued at $769,000. Vanguard Group Inc. grew its stake in shares of Organon & Co. by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock valued at $578,849,000 after buying an additional 192,613 shares during the period. Public Sector Pension Investment Board increased its holdings in shares of Organon & Co. by 8.0% during the 2nd quarter. Public Sector Pension Investment Board now owns 565,866 shares of the company’s stock worth $11,713,000 after buying an additional 41,954 shares during the last quarter. Beddow Capital Management Inc. raised its position in shares of Organon & Co. by 38.8% during the 3rd quarter. Beddow Capital Management Inc. now owns 306,675 shares of the company’s stock valued at $5,867,000 after buying an additional 85,775 shares during the period. Finally, O Shaughnessy Asset Management LLC lifted its holdings in Organon & Co. by 187.1% in the first quarter. O Shaughnessy Asset Management LLC now owns 39,758 shares of the company’s stock valued at $747,000 after acquiring an additional 25,909 shares during the last quarter. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Organon & Co. Price Performance

Organon & Co. stock opened at $14.73 on Thursday. Organon & Co. has a 52-week low of $10.84 and a 52-week high of $23.10. The company’s 50 day moving average is $17.82 and its two-hundred day moving average is $19.85. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73. The firm has a market cap of $3.79 billion, a PE ratio of 2.92, a price-to-earnings-growth ratio of 0.68 and a beta of 0.84.

Organon & Co. (NYSE:OGN) last issued its quarterly earnings results on Thursday, October 31st. The company reported $0.87 earnings per share for the quarter, missing the consensus estimate of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.56 billion. During the same quarter last year, the company earned $0.78 EPS. Organon & Co.’s revenue for the quarter was up 4.1% compared to the same quarter last year. On average, research analysts expect that Organon & Co. will post 3.89 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 12th. Stockholders of record on Tuesday, November 12th will be given a dividend of $0.28 per share. The ex-dividend date is Tuesday, November 12th. This represents a $1.12 annualized dividend and a dividend yield of 7.61%. Organon & Co.’s dividend payout ratio is currently 22.22%.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Evercore ISI raised Organon & Co. to a “strong-buy” rating in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lowered shares of Organon & Co. from a “neutral” rating to an “underweight” rating and increased their target price for the stock from $18.00 to $20.00 in a research note on Friday, September 6th.

About Organon & Co.

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.